Biotech Strategy Blog
24 FOLLOWERS
Biotech Strategy Blog provides commentary and insight on new product development in the pharma and biotech industries with a focus on oncology, hematology, immunotherapy and immuno-oncology. Occasionally covered are themes such as innovation, nanotechnology, regenerative medicine, strategic issues in the biotechnology industry and promising scientific research in other therapeutic areas.
Biotech Strategy Blog
22h ago
“Each man’s death diminishes me, For I am involved in mankind. Therefore, send not to know For whom the bell ..read more
Biotech Strategy Blog
4d ago
It is very rare indeed to see first generation anti-cancer molecules hit the sweet spot against any given novel target. Those ..read more
Biotech Strategy Blog
1w ago
Not all inhibitors – even in the same class – are equal. As the flood of KRAS directed agents into ..read more
Biotech Strategy Blog
2w ago
Every now and then what seems like one player out in left field for the longest time suddenly balloons into ..read more
Biotech Strategy Blog
3w ago
Lately the cancer research space is abuzz with the promise of several novel therapeutic approaches, each touted as the next ..read more
Biotech Strategy Blog
3w ago
Inspired by some local San Diego street art during the AACR meeting last week, my thoughts were immediately drawn to ..read more
Biotech Strategy Blog
1M ago
It’s very rare for any oncology category to see lasting success with the first couple of attempts to drug a ..read more
Biotech Strategy Blog
1M ago
The AACR annual meeting is an opportunity to challenge established paradigms and scientific dogma. In this post, we’re highlighting some ..read more
Biotech Strategy Blog
1M ago
For the longest time many folks have been rather bearish when it comes to drugging seemingly intractable targets in oncology ..read more
Biotech Strategy Blog
1M ago
Have you often wondered about the challenges of going into the unknown with phase 1 or even phase 3 trials ..read more